Pimicotinib (ABSK021) is an oral, small-molecule inhibitor of colony-stimulating factor-1 receptor (CSF-1R) that is under clinical investigation in patients with tenosynovial giant cell tumor (TGCT). Pimicotinib is being developed by Abbisko Therapeutics Co. Ltd., Shanghai, China. Merck KGaA, Darmstadt, Germany holds the rights to commercialize pimicotinib worldwide.

Learn more about all pimicotinib (ABSK021) clinical trials at clinicaltrials.gov

Precemtabart tocentecan (M9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) ADC designed to deliver the TOP1-inhibitor exatecan to CEACAM5-overexpressing tumor cells that is under clinical investigation in patients with advanced colorectal cancer (CRC) and other solid tumors.

Phase 1 study in patients with advanced CRC: click here to see the PROCEADE-CRC-01 study design

Phase 1b/2 study in patients with advanced solid tumors (gastric cancer, non-small cell lung cancer, pancreatic ductal adenocarcinoma): click here to see the PROCEADE-PanTumor study design

Learn more about all precemtabart tocentecan (M9140) clinical trials at clinicaltrials.gov

Click here to find participating sites for currently recruiting precemtabart tocentecan (M9140) clinical trials

M3554 is an anti-GD2 ADC with a unique linker-payload combination to selectively deliver the TOP1-inhibitor exatecan to GD2 overexpressing tumor cells that is under clinical investigation in patients with soft tissue sarcoma and glioblastoma.

Phase 1 study in patients with soft tissue sarcoma and glioblastoma: click here to see the study design

Learn more about all M3554 clinical trials at clinicaltrials.gov

Click here to find participating sites for currently recruiting M3554 clinical trials

Tuvusertib is an ATR (ataxia telangiectasia and Rad3 related kinase) inhibitor under clinical investigation in patients with advanced solid tumors, including epithelial ovarian cancer and prostate cancer.

Phase 2 study in patients with epithelial ovarian cancer (tuvusertib in combination with lartesertib or niraparib): click here to see the DDRiver 302 study design

Phase 1 study in patients with advanced solid tumors (tuvusertib in combination with niraparib): click here to see the DDRiver 301 study design

Phase 1 study in patients with advanced solid tumors (tuvusertib in combination with lartesertib or avelumab): click here to see the DDRiver 320 study design

Phase 1 study in patients with advanced solid tumors, including prostate cancer (M9466 alone or in combination with tuvusertib or abiraterone acetate and prednisone): click here to see the DDRiver 501 study design

Learn more about all tuvusertib clinical trials at clinicaltrials.gov

Click here to find participating sites for currently recruiting tuvusertib clinical trials

Lartesertib is an ATM (ataxia telangiectasia mutated kinase) inhibitor under clinical investigation in patients with advanced solid tumors, including ovarian cancer.

Phase 2 study in patients with epithelial ovarian cancer (tuvusertib in combination with lartesertib or niraparib): click here to see the DDRiver 302 study design

Phase 1 study in patients with advanced solid tumors (tuvusertib in combination with lartesertib or avelumab): click here to see the DDRiver 320 study design

Learn more about all lartesertib clinical trials at clinicaltrials.gov

Click here to find participating sites for currently recruiting lartesertib clinical trials

M9466 is a PARP1 (poly (ADP-ribose) polymerase 1) inhibitor under clinical investigation in patients with advanced solid tumors, including prostate cancer, colorectal cancer, and small-cell lung cancer.

The Healthcare business of Merck KGaA, Darmstadt, Germany obtained exclusive rights from Jiangsu Hengrui Pharmaceuticals Co., Ltd. to develop, manufacture, and commercialize M9466 (also known as HRS-1167) outside China.

Phase 1 study in patients with advanced solid tumors, including prostate cancer (M9466 alone or in combination with tuvusertib or abiraterone acetate and prednisone): click here to see the DDRiver 501 study design

Phase 1 study in patients with advanced solid tumors, including colorectal cancer (M9466 in combination with FOLFIRI and bevacizumab): click here to see the DDRiver 511 study design

Phase 1 study in patients with advanced solid tumors, including small cell lung cancer (M9466 in combination with carboplatin, etoposide, and atezolizumab): click here to see the DDRiver 521 study design

Learn more about all M9466 clinical trials at clinicaltrials.gov

Click here to find participating sites for currently recruiting M9466 clinical trials

Avelumab is an anti-PD-L1 antibody under clinical investigation in patients with solid tumors.

Phase 2 study in patients with locally advanced or metastatic urothelial carcinoma (avelumab alone or in combination with sacituzumab govitecan, M6223, or NKTR-255 as a maintenance treatment): click here to see the JAVELIN Bladder Medley study design

Learn more about all avelumab clinical trials at clinicaltrials.gov

Click here to find participating sites for currently recruiting avelumab clinical trials

M6223 is an anti-TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains) antibody under clinical investigation in patients with solid tumors.

Phase 2 study in patients with locally advanced or metastatic urothelial carcinoma (avelumab alone or in combination with sacituzumab govitecan, M6223, or NKTR-255 as a maintenance treatment): click here to see the JAVELIN Bladder Medley study design

Learn more about all M6223 clinical trials at clinicaltrials.gov

Click here to find participating sites for currently recruiting M6223 clinical trials